CASTOR Propels J&J's Anti-CD38 Darzalex To Prime Position In Myeloma
Lead investigator says anti-38 antibody daratumumab compares well in earlier-stage relapsed disease to other myeloma drugs and advises using it early on the basis of "unprecedented" benefit.
You may also be interested in...
ASCO's big push on providing value came through loud and clear in annual meeting sessions on multiple myeloma, breast cancer, colon cancer and renal cell carcinoma.
Darzalex made a splash with impressive Phase III data in relapsed multiple myeloma at the EHA and ASCO meetings, but a range of other drugs are on the way, including a next-generation CD38 inhibitor from Sanofi, checkpoint inhibitors and Roche's BCL-2 Venclexta.
With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.